Please complete the form below to receive relevant information from Incyte, such as further information on Opzelura® and vitiligo

First Name:

Last Name:

Institution:

E-mail Address:

Confirm E-mail Address:

Post Code:

Country:

Specialty:

Please check the boxes below before proceeding with submitting your information:

I acknowledge and have read Incyte's Privacy Policy

I certify that I am a healthcare professional practising medicine in Europe

I wish to receive e-mail communications from Incyte containing information and education relevant to my clinical practice, including disease and/or diagnostics educational material and marketing materials pertaining to Incyte medicinal products. I understand that I have the option to opt-out from receiving these emails at any time using contact details that will be provided to me with each e-mail communication or by emailing privacy@incyte.com

References

Opzelura® (ruxolitinib cream) Summary of Product Characteristics. Incyte Biosciences UK Ltd. November 2023.

UNITED KINGDOM
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Incyte immediately by calling 03301003677 (Great Britain) 00-800-0002-7423 (United Kingdom (Northern Ireland)).

REPUBLIC OF IRELAND
Adverse events should be reported. Reporting forms and information can be found at: HPRA Pharmacovigilance website: www.hpra.ie Adverse events should also be reported to Incyte by calling 00-800-0002-7423.

Opzelura® (ruxolitinib) stay informed

Please complete the form below to receive relevant information from Incyte, such as further information on Opzelura® and vitiligo

References

Opzelura® (ruxolitinib)
stay informed